Scholar Rock Holding Corporation $SRRK Shares Sold by Clearbridge Investments LLC

Clearbridge Investments LLC reduced its position in Scholar Rock Holding Corporation (NASDAQ:SRRK) by 15.2% in the 4th quarter, HoldingsChannel.com reports. The fund owned 295,475 shares of the company’s stock after selling 52,974 shares during the quarter. Clearbridge Investments LLC’s holdings in Scholar Rock were worth $13,016,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. JPMorgan Chase & Co. grew its position in shares of Scholar Rock by 161.0% during the third quarter. JPMorgan Chase & Co. now owns 713,988 shares of the company’s stock worth $26,589,000 after buying an additional 440,401 shares in the last quarter. Jennison Associates LLC grew its position in shares of Scholar Rock by 74.0% during the fourth quarter. Jennison Associates LLC now owns 2,795,188 shares of the company’s stock worth $123,128,000 after buying an additional 1,188,676 shares in the last quarter. HighVista Strategies LLC grew its position in shares of Scholar Rock by 90.8% during the third quarter. HighVista Strategies LLC now owns 59,573 shares of the company’s stock worth $2,218,000 after buying an additional 28,343 shares in the last quarter. Eagle Health Investments LP grew its position in shares of Scholar Rock by 34.9% during the third quarter. Eagle Health Investments LP now owns 363,300 shares of the company’s stock worth $13,529,000 after buying an additional 93,900 shares in the last quarter. Finally, Granahan Investment Management LLC grew its position in shares of Scholar Rock by 77.1% during the third quarter. Granahan Investment Management LLC now owns 129,914 shares of the company’s stock worth $4,838,000 after buying an additional 56,539 shares in the last quarter. 91.08% of the stock is owned by institutional investors and hedge funds.

Scholar Rock Stock Performance

Shares of SRRK opened at $44.09 on Thursday. The stock has a 50 day moving average price of $48.07 and a 200 day moving average price of $45.80. The company has a quick ratio of 8.64, a current ratio of 8.64 and a debt-to-equity ratio of 0.71. The company has a market capitalization of $5.28 billion, a price-to-earnings ratio of -12.28 and a beta of 0.69. Scholar Rock Holding Corporation has a 52-week low of $27.07 and a 52-week high of $52.19.

Scholar Rock (NASDAQ:SRRK) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.83) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.01). During the same quarter in the previous year, the business earned ($0.67) earnings per share. Research analysts predict that Scholar Rock Holding Corporation will post -3.23 EPS for the current fiscal year.

Insiders Place Their Bets

In other Scholar Rock news, insider Akshay Vaishnaw sold 12,246 shares of the business’s stock in a transaction that occurred on Thursday, April 16th. The stock was sold at an average price of $49.57, for a total value of $607,034.22. Following the completion of the sale, the insider owned 630,542 shares in the company, valued at approximately $31,255,966.94. The trade was a 1.91% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Vikas Sinha sold 10,410 shares of the business’s stock in a transaction that occurred on Thursday, April 16th. The shares were sold at an average price of $49.57, for a total value of $516,023.70. Following the completion of the sale, the chief financial officer owned 619,856 shares of the company’s stock, valued at approximately $30,726,261.92. This represents a 1.65% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders sold 63,491 shares of company stock valued at $3,147,249. 13.30% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of equities analysts have recently commented on the company. Canaccord Genuity Group assumed coverage on Scholar Rock in a research report on Monday, April 20th. They set a “buy” rating and a $62.00 price objective for the company. Truist Financial boosted their price objective on Scholar Rock from $44.00 to $55.00 and gave the stock a “buy” rating in a research report on Tuesday, March 3rd. Citigroup boosted their price objective on Scholar Rock from $55.00 to $58.00 and gave the stock a “buy” rating in a research report on Wednesday, March 4th. BMO Capital Markets boosted their price objective on Scholar Rock from $50.00 to $70.00 and gave the stock an “outperform” rating in a research report on Wednesday, March 4th. Finally, Piper Sandler boosted their price objective on Scholar Rock from $51.00 to $58.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 4th. Four equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $56.00.

Scholar Rock Company Profile

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).